Can Unresectable Colorectal Cancer Be Cured?

Kellie L. Mathis, Heidi Nelson, John H. Pemberton

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A multimodality regimen that includes EBRT, chemotherapy, maximal surgical resection, and IORT, when used in patients with initially unresectable primary colon or rectal adenocarcinoma, is associated with excellent long-term local control, and a 5-year overall survival of 52%. Distant metastases account for most treatment failures, occurring in roughly 50%. Treatment-related morbidity is high, with a long-term complication rate that approaches 50%. These results suggest that selected patients with advanced unresectable disease benefit from an aggressive approach. Additional effort needs to focus on reducing the rate of systemic failure with more effective chemotherapy regimens and minimizing the frequency of long-term procedural complications.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalAdvances in Surgery
Volume43
Issue number1
DOIs
StatePublished - Sep 2009

Fingerprint

Colorectal Neoplasms
Drug Therapy
Treatment Failure
Colon
Adenocarcinoma
Neoplasm Metastasis
Morbidity
Survival
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Can Unresectable Colorectal Cancer Be Cured? / Mathis, Kellie L.; Nelson, Heidi; Pemberton, John H.

In: Advances in Surgery, Vol. 43, No. 1, 09.2009, p. 211-219.

Research output: Contribution to journalArticle

Mathis, Kellie L. ; Nelson, Heidi ; Pemberton, John H. / Can Unresectable Colorectal Cancer Be Cured?. In: Advances in Surgery. 2009 ; Vol. 43, No. 1. pp. 211-219.
@article{5941b6e2c62543478b556b847bfe4b67,
title = "Can Unresectable Colorectal Cancer Be Cured?",
abstract = "A multimodality regimen that includes EBRT, chemotherapy, maximal surgical resection, and IORT, when used in patients with initially unresectable primary colon or rectal adenocarcinoma, is associated with excellent long-term local control, and a 5-year overall survival of 52{\%}. Distant metastases account for most treatment failures, occurring in roughly 50{\%}. Treatment-related morbidity is high, with a long-term complication rate that approaches 50{\%}. These results suggest that selected patients with advanced unresectable disease benefit from an aggressive approach. Additional effort needs to focus on reducing the rate of systemic failure with more effective chemotherapy regimens and minimizing the frequency of long-term procedural complications.",
author = "Mathis, {Kellie L.} and Heidi Nelson and Pemberton, {John H.}",
year = "2009",
month = "9",
doi = "10.1016/j.yasu.2009.02.006",
language = "English (US)",
volume = "43",
pages = "211--219",
journal = "Advances in Surgery",
issn = "0065-3411",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Can Unresectable Colorectal Cancer Be Cured?

AU - Mathis, Kellie L.

AU - Nelson, Heidi

AU - Pemberton, John H.

PY - 2009/9

Y1 - 2009/9

N2 - A multimodality regimen that includes EBRT, chemotherapy, maximal surgical resection, and IORT, when used in patients with initially unresectable primary colon or rectal adenocarcinoma, is associated with excellent long-term local control, and a 5-year overall survival of 52%. Distant metastases account for most treatment failures, occurring in roughly 50%. Treatment-related morbidity is high, with a long-term complication rate that approaches 50%. These results suggest that selected patients with advanced unresectable disease benefit from an aggressive approach. Additional effort needs to focus on reducing the rate of systemic failure with more effective chemotherapy regimens and minimizing the frequency of long-term procedural complications.

AB - A multimodality regimen that includes EBRT, chemotherapy, maximal surgical resection, and IORT, when used in patients with initially unresectable primary colon or rectal adenocarcinoma, is associated with excellent long-term local control, and a 5-year overall survival of 52%. Distant metastases account for most treatment failures, occurring in roughly 50%. Treatment-related morbidity is high, with a long-term complication rate that approaches 50%. These results suggest that selected patients with advanced unresectable disease benefit from an aggressive approach. Additional effort needs to focus on reducing the rate of systemic failure with more effective chemotherapy regimens and minimizing the frequency of long-term procedural complications.

UR - http://www.scopus.com/inward/record.url?scp=70350054649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350054649&partnerID=8YFLogxK

U2 - 10.1016/j.yasu.2009.02.006

DO - 10.1016/j.yasu.2009.02.006

M3 - Article

C2 - 19845180

AN - SCOPUS:70350054649

VL - 43

SP - 211

EP - 219

JO - Advances in Surgery

JF - Advances in Surgery

SN - 0065-3411

IS - 1

ER -